Drug Profile

Sodium valproate - Kowa

Alternative Names: K 828; K-828-AB; K-828-SP; Valproate sodium

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kowa
Class Antidementias; Antiepileptic drugs; Small molecules
Mechanism of Action 4-aminobutyrate transaminase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Spinal muscular atrophy
New Molecular Entity Yes

Highest Development Phases

Discontinued Dementia; Spinal muscular atrophy

Most Recent Events

24 Sep 2021 Discontinued - Phase-III for Spinal muscular atrophy in Japan (PO)
30 Sep 2018 Kowa Pharmaceuticals completes phase III trial in Spinal muscular atrophy in Japan (In children) (JapicCTI-163450)
12 Oct 2016 Chemical structure information added

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com